{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:37Z","timestamp":1780987957419,"version":"3.54.1"},"reference-count":40,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2651055","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:12:58Z","timestamp":1775488378000},"page":"1089-1098","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6621-8342","authenticated-orcid":false,"given":"Joshua A.","family":"Roth","sequence":"first","affiliation":[{"name":"Global Access and Value, Pfizer","place":["New York, USA"]},{"name":"School of Pharmacy, University of Washington","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kratochvil","sequence":"additional","affiliation":[{"name":"OPEN Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Perkins","sequence":"additional","affiliation":[{"name":"Global Access and Value, Pfizer","place":["New York, USA"]},{"name":"School of Pharmacy, University of Washington","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"OPEN Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3237"},{"key":"e_1_3_3_3_1","volume-title":"Genentech, Inc. One DNA Way","author":"RUXIENCE (rituximab) [package insert]","year":"2010","unstructured":"RUXIENCE (rituximab) [package insert]. Genentech, Inc. One DNA Way. South San Francisco, CA. US Food and Drug Administration; 2010, February."},{"key":"e_1_3_3_4_1","unstructured":"cancerNetwork. Rituxan Plus CHOP Approved for Diffuse Large B-Cell Lymphoma 2006. Available from: https:\/\/www.cancernetwork.com\/view\/rituxan-plus-chop-approved-diffuse-large-b-cell-lymphoma."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-586"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.11.004"},{"key":"e_1_3_3_8_1","unstructured":"US Food and Drug Administration. What is a Biosimilar. Available from: https:\/\/www.fda.gov\/media\/108905\/download."},{"key":"e_1_3_3_9_1","unstructured":"Lymphoma Research Foundation. US Food and Drug Administration Approves Biosimilar Rituximab-pvvr Ruxience for CD20 Positive Non-Hodgkin B-Cell Lymphomas and Chronic Lymphocytic Leukemia 2019. Available from: https:\/\/lymphoma.org\/news\/u-s-food-and-drug-administration-approves-biosimilar-rituximab-pvvr-ruxience-for-cd20-positive-non-hodgkin-b-cell-lymphomas-and-chronic-lymphocytic-leukemia\/."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23586"},{"key":"e_1_3_3_11_1","volume-title":"Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product","author":"US Food and Drug Administration","year":"2012","unstructured":"US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Rockville (MD): US Food and Drug Administration; 2012."},{"key":"e_1_3_3_12_1","volume-title":"CELLTRION, Inc. 20, Academy-ro 51 beon-gil","author":"TRUXIMA (rituximab-abbs) [package insert]","year":"2022","unstructured":"TRUXIMA (rituximab-abbs) [package insert]. CELLTRION, Inc. 20, Academy-ro 51 beon-gil. Yeonsu-gu, Incheon, 22014 Republic of Korea US Food and Drug Administration; 2022."},{"key":"e_1_3_3_13_1","unstructured":"RIABNI (rituximab-arrx) [package insert]. Amgen Inc. One Amgen Center Drive Thousand Oaks CA December US Food and Drug Administration; 2020."},{"key":"e_1_3_3_14_1","unstructured":"CMS. Medicare Part B Drug Spending Dashboard. A dashboard providing spending information for Medicare Part B drugs paid through the Medicare program. 2022; [cited 2024]. Available from: https:\/\/data.cms.gov\/tools\/medicare-part-b-drug-spending-dashboard."},{"key":"e_1_3_3_15_1","unstructured":"ASPE Office of Health Policy. Medicare Part B enrollee use and spending on biosimilars 2018\u20132023. [updated January 15 2025]. Available from: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/be065dbbd1f866c65cf627995bd2ea56\/biosimilars-medicare-part-b.pdf."},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211407367"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2226007"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146935"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e18837"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1833339"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2331905"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1358173"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1928515"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1916863"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119060-00001"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2183680"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00187.x"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00045.x"},{"key":"e_1_3_3_30_1","unstructured":"Administration FaD. Biological Product Definitions: U.S. Food & Drug Administration; [cited 2024 July 1]. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Biological-Product-Definitions.pdf."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7173"},{"key":"e_1_3_3_32_1","unstructured":"CMS. Medicare Monthly Enrollment. 2026. Available from: https:\/\/data.cms.gov\/summary-statistics-on-beneficiary-enrollment\/medicare-and-medicaid-reports\/medicare-monthly-enrollment."},{"key":"e_1_3_3_33_1","unstructured":"Gandhi S. Diffuse Large B-Cell Lymphoma (DLBCL) Guidelines. 2025. Available from: https:\/\/emedicine.medscape.com\/article\/202969-guidelines."},{"key":"e_1_3_3_34_1","unstructured":"CMS. Payment Allowance Limits for Medicare Part B Drugs: centers for Medicare & Medicaid Services. 2024; [cited 2024 July]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files."},{"key":"e_1_3_3_35_1","volume-title":"Micromedex RedBOOK","author":"IBM","year":"2024","unstructured":"IBM. Micromedex RedBOOK. Armonk (NY): IBM; 2024."},{"key":"e_1_3_3_36_1","unstructured":"CMS. Hospital Outpatient PPS. 2023; [cited 2023 October 3]. Available from https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/hospital-outpatient#:\u223c:text=Section%2011403%20of%20the%20Inflation ASP%20of%20the%20reference%20biological."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9300"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000142"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106591"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1760284"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2474884"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2651055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:13:01Z","timestamp":1775488381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2651055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2651055"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2651055","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}